# 2026-05618: DEA Bans Mind-Bending 3-MeO-PCP in Schedule I Crackdown

2026-05618, Schedules of Controlled Substances: Placement of 3-Methoxyphencyclidine (1-(1-(3-Methoxyphenyl)cyclohexyl)piperidine) in Schedule I, is a Federal Register rule from Justice Department, Drug Enforcement Administration published 2026-03-23, effective 2026-04-22; PRIA reads it as touching household money (as of 2026-06-11).

- Canonical: https://policyrisk.com/federal-register/2026-05618
- As of: 2026-06-11
- Plain-text twin of the page above; the HTML and this file carry the same facts.

## Facts
- Document number: 2026-05618
- Title: Schedules of Controlled Substances: Placement of 3-Methoxyphencyclidine (1-(1-(3-Methoxyphenyl)cyclohexyl)piperidine) in Schedule I
- Type: Rule
- Agencies: Justice Department; Drug Enforcement Administration
- Citation: 91 FR 13733
- Published: 2026-03-23
- Effective: 2026-04-22
- Comments close: not stated
- Significant: no
- Touches household money: yes
- Regulation identifier numbers: none
- Last updated: 2026-06-11

## In one line

DEA Bans Mind-Bending 3-MeO-PCP in Schedule I Crackdown

## Summary

Starting April 22, 2026, the DEA is putting 3-methoxyphencyclidine (3-MeO-PCP) into Schedule I, meaning it’s now officially a highly controlled substance with strict rules. This affects anyone who makes, sells, studies, or even possesses 3-MeO-PCP, who will face serious legal consequences. This move helps the U.S. follow international drug laws and keeps communities safer.

## Abstract

With the issuance of this final rule, the Drug Enforcement Administration places substance 3-methoxyphencyclidine (1-(1-(3- methoxyphenyl)cyclohexyl)piperidine; 3-MeO-PCP), including its salts, isomers, and salts of isomers, in schedule I of the Controlled Substances Act. This action is being taken, in part, to enable the United States to meet its obligations under the 1971 Convention on Psychotropic Substances. This action imposes the regulatory controls and administrative, civil, and criminal sanctions applicable to schedule I controlled substances on persons who handle (manufacture, distribute, reverse distribute, import export, engage in research, conduct instructional activities or chemical analysis with, or possess) or propose to handle 3-MeO-PCP.

## Effects PRIA read

- 3‑MeO‑PCP Placed Into Schedule I: cost, high. Starting April 22, 2026, the Drug Enforcement Administration places 3-methoxyphencyclidine (3-MeO-PCP) in Schedule I of the Controlled Substances Act. That means possession, manufacture, distribution, importation, exportation, or other handling of 3-MeO-PCP is subject to the strict criminal, civil,…
- DEA Registration Required to Handle 3‑MeO‑PCP: cost, medium. If you handle 3-MeO-PCP (manufacture, distribute, research with, import, export, or possess), you must register with DEA under 21 U.S.C. 822, 823, 957, and 958 and follow 21 CFR parts 1301 and 1312. Any person who currently handles 3-MeO-PCP and is not registered must submit an application and may…
- Strict Compliance Rules for Registrants: cost, medium. DEA registrants handling 3-MeO-PCP must follow Schedule I controls including security requirements, labeling and packaging rules, quotas for manufacture, and recordkeeping and reporting. Registrants must take an initial inventory on the date they first handle controlled substances and thereafter in…
- Research Allowed but Requires Schedule I Registration: cost, low. The final rule states that placing 3-MeO-PCP in Schedule I does not preclude research, but researchers must comply with DEA's Schedule I registration processes and requirements to conduct research legally. Those who wish to study 3-MeO-PCP must follow the DEA registration process for Schedule I sub…
- DEA Says Limited Small‑Entity Economic Impact: benefit, low. DEA certifies under the Regulatory Flexibility Act that this final rule will not have a significant economic impact on a substantial number of small entities. The agency notes there appear to be no legitimate marketed sources for 3-MeO-PCP in the U.S., though legitimate suppliers sell it for scient…

## Related documents

- [2026-11526](https://policyrisk.com/federal-register/2026-11526): Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 201…, 2026-06-09
- [2026-10128](https://policyrisk.com/federal-register/2026-10128): Revision of Applications for Manufacturing and Procurement Quotas, 2026-05-20
- [2025-05007](https://policyrisk.com/federal-register/2025-05007): Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients, 2025-03-24
- [2025-02793](https://policyrisk.com/federal-register/2025-02793): Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients, 2025-02-19
- [2026-22843](https://policyrisk.com/federal-register/2026-22843): Proposed Aggregate Production Quotas for Schedule I and II Controlled Substances and Assessment of Annual Needs for the List I Chemicals Ep…, 2026-11-10
- [2026-22842](https://policyrisk.com/federal-register/2026-22842): Adjustment to the 2026 Aggregate Production Quota for d,l-Amphetamine, d-Amphetamine (for Sale), Hydromorphone and Methylphenidate (for Sal…, 2026-11-10

## Sources
- [2026-05618 on federalregister.gov](https://www.federalregister.gov/documents/2026/03/23/2026-05618/schedules-of-controlled-substances-placement-of-3-methoxyphencyclidine)
- [2026-05618 as published (PDF)](https://www.govinfo.gov/content/pkg/FR-2026-03-23/pdf/2026-05618.pdf)

## Related
- [Previous: 2026-05607, Air Plan Approval; Texas; Reasonably Available Control Technology in the Dallas…](https://policyrisk.com/federal-register/2026-05607)
- [Next: 2026-05634, Minor Child Definition for Form LM-30 Labor Organization Officer and Employee R…](https://policyrisk.com/federal-register/2026-05634)
- [All Federal Register documents](https://policyrisk.com/federal-register)

Source: PRIA, https://policyrisk.com/federal-register/2026-05618 (as of 2026-06-11).
